{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:38:12Z","timestamp":1781890692434,"version":"3.54.5"},"update-to":[{"DOI":"10.1002\/14651858.cd004314.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T00:00:00Z","timestamp":1477440000000}}],"reference-count":86,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004314.pub3","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T09:49:49Z","timestamp":1477475389000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Botulinum toxin type A versus botulinum toxin type B for cervical dystonia"],"prefix":"10.1002","volume":"2016","author":[{"given":"Gon\u00e7alo S","family":"Duarte","sequence":"first","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Avenida Professor Egas Moniz Lisboa Lisboa Portugal 1649-028"},{"name":"Instituto de Medicina Molecular; Clinical Pharmacology Unit; Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafalda","family":"Castel\u00e3o","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Avenida Professor Egas Moniz Lisboa Lisboa Portugal 1649-028"},{"name":"Instituto de Medicina Molecular; Clinical Pharmacology Unit; Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe B","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Avenida Professor Egas Moniz Lisboa Lisboa Portugal 1649-028"},{"name":"Instituto de Medicina Molecular; Clinical Pharmacology Unit; Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel E","family":"Marques","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Avenida Professor Egas Moniz Lisboa Lisboa Portugal 1649-028"},{"name":"Instituto de Medicina Molecular; Clinical Pharmacology Unit; Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Avenida Professor Egas Moniz Lisboa Lisboa Portugal 1649-028"},{"name":"Instituto de Medicina Molecular; Clinical Pharmacology Unit; Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[{"name":"CHDI Foundation; 155 Village Boulevard Suite 200 Princeton NJ USA 08540"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austen P","family":"Moore","sequence":"additional","affiliation":[{"name":"The Walton Centre NHS Foundation Trust; Lower Lane Liverpool UK L9 7LJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Costa","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Avenida Professor Egas Moniz Lisboa Lisboa Portugal 1649-028"},{"name":"Instituto de Medicina Molecular; Clinical Pharmacology Unit; Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,10,26]]},"reference":[{"key":"10.1002\/14651858.CD004314.pub3-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.21724","article-title":"Botulinum toxin type B vs. type A in toxin-na\u00efve patients with cervical dystonia: randomized double-blind, noninferiority trial","volume":"23","author":"Pappert","year":"2008","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1212\/01.wnl.0000174433.76707.8c","article-title":"Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial","volume":"65","author":"Tintner","year":"2005","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1002\/sim.2423","article-title":"Meta-analysis of heterogeneously reported trials assessing change from baseline","volume":"24","author":"Abrams","year":"2005","journal-title":"Statistics in Medicine"},{"issue":"7","key":"10.1002\/14651858.CD004314.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.25475","article-title":"Phenomenology and classification of dystonia: a consensus update","volume":"28","author":"Albanese","year":"2013","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1002\/14651858.CD004314.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2288-2-3","article-title":"Meta-analysis, Simpson's paradox, and the number needed to treat","volume":"2","author":"Altman","year":"2002","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"3689\u201396","DOI":"10.1523\/JNEUROSCI.0375-08.2008","article-title":"Long-distance retrograde effects of botulinum neurotoxin","volume":"28","author":"Antonucci","year":"2008","journal-title":"Journal of Neuroscience"},{"issue":"4","key":"10.1002\/14651858.CD004314.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/ene.12650","article-title":"Isolated and combined dystonia syndromes - an update on new genes and their phenotypes","volume":"22","author":"Balint","year":"2015","journal-title":"European Journal of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD004314.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD004314.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599840-000000000-00000","article-title":"Clinical Relevance of Botulinum Toxin Immunogenicity","volume":"26","author":"Benecke","year":"2012","journal-title":"BioDrugs"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.toxicon.2015.08.001","article-title":"Clinical differences between botulinum neurotoxin type A and B","volume":"107","author":"Bentivoglio","year":"2015","journal-title":"Toxicon"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0012|cit12","unstructured":"British National Formulary Botulinum toxin type A National Institute for Health and Care Excellence May 2016"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0013|cit13","unstructured":"British National Formulary Botulinum toxin type B National Institute for Health and Care Excellence May 2016"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0014|cit14","first-page":"495\u2013504","article-title":"On the question of permeability of the blood\u2013brain barrier to botulinum toxin","volume":"48","author":"Boroff","year":"1975","journal-title":"International Archives of Allergy and Applied Immunology"},{"issue":"2","key":"10.1002\/14651858.CD004314.pub3-BIB0015|cit15","first-page":"58","article-title":"Botulinum toxin serotype A for cervical dystonia\u2014an assessment","volume":"4","author":"Brashear","year":"2008","journal-title":"US Neurology"},{"issue":"10","key":"10.1002\/14651858.CD004314.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay","volume":"23","author":"Brin","year":"2008","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1477-7525-4-69","article-title":"How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure","volume":"4","author":"Bro\u017cek","year":"2006","journal-title":"Health and Quality of Life Outcomes"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0018|cit18","doi-asserted-by":"crossref","DOI":"10.1002\/9781119942283","volume-title":"Multiple Imputation and its Application","author":"Carpenter","year":"2013"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.870060206","article-title":"Idiopathic cervical dystonia: clinical characteristics","volume":"6","author":"Chan","year":"1991","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0020|cit20","volume-title":"Statistical Power Analysis in the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"2","key":"10.1002\/14651858.CD004314.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mdc3.12131","article-title":"Development of the comprehensive Cervical Dystonia Rating Scale: methodology","volume":"2","author":"Comella","year":"2015","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0022|cit22","first-page":"211","article-title":"Clinical assessments of patients with cervical dystonia","volume-title":"Therapy with Botulinum Toxin","author":"Consky","year":"1994"},{"issue":"1","key":"10.1002\/14651858.CD004314.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jrsm.1090","article-title":"Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool","volume":"5","author":"Corbett","year":"2014","journal-title":"Research Synthesis Methods"},{"issue":"1","key":"10.1002\/14651858.CD004314.pub3-BIB0024|cit24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003633.pub2","article-title":"Botulinum toxin type A therapy for cervical dystonia","author":"Costa","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0025|cit25","first-page":"29","article-title":"Safety and tolerability of repeated doses of Neurobloc (Botulinum toxin type B) in patients with cervical dystonia: an open-label, dose-escalation study","volume":"15 (Suppl 2)","author":"Cullis","year":"2000","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0026|cit26","first-page":"3200\u20135","article-title":"Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals","volume":"96","author":"Paiva","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"tre","DOI":"10.5334\/tohm.170","article-title":"Descriptive epidemiology of cervical dystonia","volume":"3","author":"Defazio","year":"2013","journal-title":"Tremor and Other Hyperkinetic Movements"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0022-510X(71)90129-8","article-title":"An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse","volume":"14","author":"Duchen","year":"1971","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"10.1002\/14651858.CD004314.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0304-3940(97)13448-6","article-title":"Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human","volume":"224","author":"Eleopra","year":"1997","journal-title":"Neuroscience Letters"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s004150070094","article-title":"A prevalence study of primary dystonia in eight European countries","volume":"247","author":"Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group","year":"2000","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12640-015-9565-5","article-title":"Neutralizing antibody and botulinum toxin therapy: a systematic review and meta-analysis","volume":"29","author":"Fabbri","year":"2015","journal-title":"Neurotoxicity Research"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"400\u20134","DOI":"10.3109\/00016489309135834","article-title":"Botulinum A toxin effects on rat jaw muscle spindles","volume":"113","author":"Filippi","year":"1993","journal-title":"Acta Oto-laryngologica"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3171\/jns.1959.16.1.0055","article-title":"Experimental spasmodic torticollis","volume":"16","author":"Foltz","year":"1959","journal-title":"Journal of Neurosurgery"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0035|cit35","first-page":"325","article-title":"Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?","volume":"4","author":"Frevert","year":"2010 Dec","journal-title":"Biologics: Targets & Therapy"},{"issue":"1","key":"10.1002\/14651858.CD004314.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0037|cit37","unstructured":"GRADE Working Group, McMaster University GRADEpro GDT 2014"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/mds.870080411","article-title":"Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A","volume":"8(4)","author":"Greene","year":"1993","journal-title":"Movement Disorders"},{"issue":"12","key":"10.1002\/14651858.CD004314.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence - imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD004314.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archneur.55.5.601","article-title":"The neurophysiology of dystonia","volume":"55","author":"Hallett","year":"1998","journal-title":"Archives of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD004314.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1212\/WNL.50.6.1624","article-title":"Mouse bioassay versus western blot assay for botulinum toxin antibodies: correlation with clinical response","volume":"50","author":"Hanna","year":"1998","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0042|cit42","volume-title":"Statistical Methods for Meta-Analysis","author":"Hedges","year":"1985"},{"issue":"7414","key":"10.1002\/14651858.CD004314.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"557\u201360","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0044|cit44","unstructured":"Higgins JP Deeks JJ editor(s) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0045|cit45","unstructured":"Higgins JPT Altman DG Sterne JAC editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0046|cit46","unstructured":"Higgins JPT Deeks JJ Altman DG editor(s) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1167\u201379","DOI":"10.1016\/0306-4522(81)90081-6","article-title":"Nerve growth in botulinum toxin poisoned muscles","volume":"6","author":"Holland","year":"1981","journal-title":"Neuroscience"},{"issue":"8","key":"10.1002\/14651858.CD004314.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"e011890","DOI":"10.1136\/bmjopen-2016-011890","article-title":"False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review","volume":"6","author":"Imberger","year":"2016","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/archneur.1990.00530050070014","article-title":"Natural history of adult-onset idiopathic torticollis","volume":"47","author":"Jahnanshani","year":"1990","journal-title":"Archives of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD004314.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2288-14-120","article-title":"Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods","volume":"14","author":"Jakobsen","year":"2014","journal-title":"BMC Medical Research Methodology"},{"issue":"7","key":"10.1002\/14651858.CD004314.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/jnnp.2003.034702","article-title":"Botulinum toxin in clinical practice","volume":"75","author":"Jankovic","year":"2004","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD004314.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.parkreldis.2007.02.005","article-title":"Prevalence of cervical dystonia and spasmodic torticollis in the United States general population","volume":"13","author":"Jankovic","year":"October 2007","journal-title":"Parkinsonism & Related Disorders"},{"issue":"3","key":"10.1002\/14651858.CD004314.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0960-8966(96)00041-7","article-title":"Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle","volume":"6","author":"Juzans","year":"1996","journal-title":"Neuromuscular Disorders"},{"issue":"4","key":"10.1002\/14651858.CD004314.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","article-title":"Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?","volume":"32","author":"Lange","year":"2009","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1745-6215-15-49","article-title":"Developing core outcomes sets: methods for identifying and including patient-reported outcomes (PROs)","volume":"15","author":"Macefield","year":"2014","journal-title":"Trials"},{"issue":"5","key":"10.1002\/14651858.CD004314.pub3-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004315.pub3","article-title":"Botulinum toxin type B for cervical dystonia","author":"Marques","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0058|cit58","first-page":"39\u201359","article-title":"Botulinum toxin A, brain and pain","volume":"119-20","author":"Matak","year":"2014","journal-title":"Progress in Neurobiology"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tox.2015.07.003","article-title":"Botulinum neurotoxin type A: actions beyond SNAP-25?","volume":"335","author":"Matak","year":"2015","journal-title":"Toxicology"},{"issue":"1","key":"10.1002\/14651858.CD004314.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1017\/S0266462305050154","article-title":"Meta-analysis when only the median survival times are known: a comparison with individual patient data results","volume":"21","author":"Michiels","year":"2005","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"5","key":"10.1002\/14651858.CD004314.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00702-009-0223-z","article-title":"Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity","volume":"116","author":"M\u00fcller","year":"2009","journal-title":"Journal of Neural Transmission"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials","volume":"35","author":"O\u2019Brien","year":"1979","journal-title":"Biometrics"},{"issue":"1","key":"10.1002\/14651858.CD004314.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"54\u201360","DOI":"10.1016\/j.clinph.2011.05.032","article-title":"Neurophysiological changes after intramuscular injection of botulinum toxin","volume":"123","author":"Palomar","year":"2012","journal-title":"Clinical Neurophysiology"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0064|cit64","first-page":"259\u201368","article-title":"Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses","volume":"354","author":"Pellizzari","year":"1999","journal-title":"Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences"},{"issue":"6","key":"10.1002\/14651858.CD004314.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jama.295.6.676","article-title":"Comparison of two methods to detect publication bias in meta-analysis","volume":"295","author":"Peters","year":"2006","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0066|cit66","unstructured":"The Nordic Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"488\u201396","DOI":"10.1002\/(SICI)1097-4598(199604)19:4<488::AID-MUS9>3.0.CO;2-8","article-title":"Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection","volume":"19","author":"Rosales","year":"1996","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"71\u201380","DOI":"10.1111\/j.1468-1331.2010.03056.x","article-title":"On muscle spindles, dystonia and botulinum toxin","volume":"17","author":"Rosales","year":"2010","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"585\u201398","DOI":"10.1002\/sim.4780100410","article-title":"Multiple imputation in health-care databases: an overview and some applications","volume":"10","author":"Rubin","year":"1991","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0070|cit70","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.pharmtox.44.101802.121554","article-title":"Identification of the major steps in botulinum toxin action","volume":"44","author":"Simpson","year":"2004","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1136\/bmj.318.7197.1548","article-title":"Numbers needed to treat derived from meta-analysis - sometimes informative, usually misleading","volume":"318(7197)","author":"Smeeth","year":"1999","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0073|cit73","unstructured":"StataCorp Stata Statistical Software: release 14 2015"},{"issue":"14","key":"10.1002\/14651858.CD004314.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/mds.25244","article-title":"The prevalence of primary dystonia: a systematic review and meta-analysis","volume":"27","author":"Steeves","year":"2012","journal-title":"Movement Disorders"},{"issue":"10","key":"10.1002\/14651858.CD004314.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0076|cit76","unstructured":"Sterne JAC Egger M Moher D editor(s) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0077|cit77","first-page":"818","article-title":"Dystonia","volume":"355","author":"Tarsy","year":"2006","journal-title":"New Egyptian Journal of Medicine"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0078|cit78","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User manual for trial sequential analysis (TSA) ctu.dk\/tsa\/files\/tsa \u0307manual.pdf 2011"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0079|cit79","unstructured":"Copenhagen Trial Unit Trial Sequential Analysis. Version 0.9 Beta 2011"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1745-6215-8-38","article-title":"OMERACT: an international initiative to improve outcome measurement in rheumatology","volume":"8","author":"Tugwell","year":"2007","journal-title":"Trials"},{"issue":"2","key":"10.1002\/14651858.CD004314.pub3-BIB0081|cit81","first-page":"31","article-title":"Comparison and overview of currently available neurotoxins","volume":"7","author":"Walker","year":"2014","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD004314.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"issue":"4","key":"10.1002\/14651858.CD004314.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jclinepi.2005.08.017","article-title":"A systematic review identifies a lack of standardization in methods for handling missing variance data","volume":"59","author":"Wiebe","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD004314.pub3-BIB0085|cit85","first-page":"2519\u201326","article-title":"Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value","volume":"259","author":"Zoons","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD004314.pub3-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004314.pub2","article-title":"Botulinum toxin type A versus botulinum toxin type B for cervical dystonia","author":"Costa","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD004314.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T03:42:46Z","timestamp":1723088566000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004314.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Movement Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,10,26]]},"references-count":86,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004314.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,26]]}}}